|
 |
Article Review/Hyperlink
|
Tan CC, Harden PN, Rodger RSC, Rowe PA, SPooner RJ, Junor
BJR, Briggs JD
Ranitidine reduces phosphate binding in dialysis
patients receiving calcium carbonate
Nephrol Dial Transplant
(May) 11:851-853 1996

Fifteen dialysis (both PD and hemo) patients underwent a double blind
crossover study to receive
ranitidine or placebo. The end-point was to evaluate the effect of
gastric pH on phosphorus levels. Each treatment period lasted 4
weeks. The elemental Ca intake in the form of calcium carbonate was 2
g with a range of 0.5-3.0. The P levels were higher during the
ranitidine phase (5.5 v. 4.9 mg/dl). The Ca and PTH levels were not
different. The authors conclude that ranitidine has a significant
adverse effect on the phosphate binding of calcium carbonate in
patients with renal failure.
Comment: By increasing gastric ph, ranitidine presumably
decreases the solubility of calcium carbonate thereby inhibiting P
binding. The overall difference in P levels was small but, in some
patients quite large. An assessment of dietary P intake was not done
and one cannot rule out increases in dietary P intake during the
ranitidine phase. It would have been interesting for them to have
also studied calcium acetate. (Jay Delmez, M.D., Washington
University at St. Louis, MO)
Related Folders: |
 |
|
|
|
|